Skip to main content
Journal cover image

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Publication ,  Journal Article
Muppidi, S; Utsugisawa, K; Benatar, M; Murai, H; Barohn, RJ; Illa, I; Jacob, S; Vissing, J; Burns, TM; Kissel, JT; Nowak, RJ; Andersen, H ...
Published in: Muscle Nerve
July 2019

INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. RESULTS: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). DISCUSSION: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Muscle Nerve

DOI

EISSN

1097-4598

Publication Date

July 2019

Volume

60

Issue

1

Start / End Page

14 / 24

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Quality of Life
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Muscle Strength
  • Middle Aged
  • Meningococcal Vaccines
  • Meningococcal Infections
  • Male
  • Longitudinal Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., … Regain Study Group, . (2019). Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve, 60(1), 14–24. https://doi.org/10.1002/mus.26447
Muppidi, Srikanth, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn, Isabel Illa, Saiju Jacob, et al. “Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.Muscle Nerve 60, no. 1 (July 2019): 14–24. https://doi.org/10.1002/mus.26447.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14–24.
Muppidi, Srikanth, et al. “Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.Muscle Nerve, vol. 60, no. 1, July 2019, pp. 14–24. Pubmed, doi:10.1002/mus.26447.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O’Brien FL, Wang JJ, Fujita KP, Howard JF, Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14–24.
Journal cover image

Published In

Muscle Nerve

DOI

EISSN

1097-4598

Publication Date

July 2019

Volume

60

Issue

1

Start / End Page

14 / 24

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Quality of Life
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Muscle Strength
  • Middle Aged
  • Meningococcal Vaccines
  • Meningococcal Infections
  • Male
  • Longitudinal Studies